Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-420 in transfusion-dependent β-thalassemia (dose-escalation, dose-finding, proof-of-concept)
2022-002395-36Phase 2Active
- Sponsor
- Pharmacosmos
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of petadeferitrin in beta thalassemia, sponsored by Pharmacosmos. Primary endpoint: Primary efficacy endpoint. Started Oct 2022; status: active.
02
Drugs
petadeferitrin
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on 2022-002395-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002395-36.